

The proposed additions to the medicines list

Broad therapeutic group ⁶	Proposed additional medicine	Rationale
Anaesthesia		
Drugs for opioid or benzodiazepine antagonism	Nalmefene	Treatment of opioid overdose
Volatile liquid anaesthetics	Methoxyflurane	For the short-term relief of moderate to severe pain after injury or during some short medical procedures
Cardiovascular		
Cardiovascular system	Mavacamten	Future proofing; to treat obstructive hypertrophic cardiomyopathy
Antiplatelet drugs	Selexipag	Antithrombotic agent for use in hospital settings
Lipid-regulating medicines	Alirocumab Inclisiran	Future proofing the list in anticipation that they may be introduced / funded into New Zealand in the near future
Central nervous system		
Dopaminergic drugs used in Parkinson's disease	Foscarbidopa Foslevodopa	Treatment of Parkinson's disease
Hypnotics	Lemborexant	Insomnia characterised by difficulties with sleep onset and/or sleep maintenance
Other nervous system drugs	Patisiran	Treatment of treat polyneuropathy of hereditary transthyretin-mediated amyloidosis
Prophylaxis of migraine	Atogepant	For migraine prophylaxis
Endocrine system		
Diabetes mellitus	Tirzepatide	Future proofing for new antidiabetic dual glucose-dependent insulintropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists tirzepatide
Immunological products and vaccines		
Immunological products and vaccines	Vaccines as a class	Future proofing the specified list for new vaccines that are approved for use in

⁶ Based on the New Zealand Formulary (NZF) v158 – 01 Aug 2025. Available from www.nzf.org.nz. Please note that the therapeutic group is not gazetted, only the chemical name.

Broad therapeutic group ⁶	Proposed additional medicine	Rationale
		<p>New Zealand against variety of infectious disease/ pandemic/ outbreaks, for example, mpox vaccine (orthopoxvirus vaccine)</p> <p>This will bring the following vaccines into the pharmacist prescribers medicines list.</p> <ul style="list-style-type: none"> • Dengue virus vaccines • Ebola vaccines • Enterovirus 71 vaccines • Mpox vaccines • Respiratory syncytial virus vaccines • Smallpox vaccine <p>Exclusion: Yellow fever vaccine unless meet WHO requirements</p>
Infections		
HIV infection	Lenacapavir	Treatment of HIV infection
Musculoskeletal and joint diseases		
Enzymes	Hyaluronidase	To improve the absorption and dispersion of parenterally (eg, subcutaneous or intramuscular) administered fluids, medicines, and contrast agents
Nutrition and blood		
Drugs used in metabolic disorders	Trientine	Treatment of Wilson's disease
Renal anaemias	Daprodustat Roxadustat	Proposal for hospital-based pharmacist prescribers working in renal services; to prescribe antianaemic preparations
Respiratory system		
Mucolytics and others	Elexacaftor Tezacaftor	<p>Proposal from hospital-based pharmacist prescribers working in respiratory services; Trikafta (ivacaftor, tezacaftor and elexacaftor) for inpatients.</p> <p>Noting that ivacaftor is already included on the gazetted list</p>
Skin		
Acne	Clascoterone	Treatment of acne
Psoriasis	Deucravacitinib	Treatment of psoriasis

The proposed deletions from the medicines list

Therapeutic group	Proposed additional medicine	Rationale
Malignant disease and immunosuppression		
Other immunomodulating drugs	Lenalidomide Pomalidomide	<p>Medical practitioners can only prescribe these medicines:</p> <ul style="list-style-type: none"> • Provisional Consent to the Distribution of New Medicines - 2024-go2115- New Zealand Gazette • https://gazette.govt.nz/notice/id/2023-go5784 <p>It is therefore inappropriate for these medicines to be included in the designated pharmacist prescriber specified prescription medicines list. It is proposed that they are removed from the medicines list.</p>